Airways allergic inflammation and L. reuterii treatment in asthmatic children

Michele Miraglia Del Giudice, N. Maiello, F. Decimo, N. Fusco, B D'Agostino B, N. Sullo, M. Capasso, V. Salpietro, E. Gitto, G. Ciprandi, G. L. Marseglia, L. Perrone

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Recently, it has been hypothesized that the oral administration of specific live probiotic strains may have therapeutic potential in the treatment of allergic inflammation. The aim of this study was to evaluate the effect of the oral L. reuteri DSM 17938 administration (1X108CFU), in airways allergic inflammation in mild persistent asthmatic children. In this DBPC randomized study we selected 50 children (6-14 years old), affected by mild persistent asthma (GINA step 2) and allergic to HDM. At the run-in period (T-2), the children were submitted to medical examination, prick tests for the main respiratory allergens, spirometry and children asthma control test (C-ACT). We selected only the children with well controlled asthma (C-ACT >19 and FEV1>80%). After two weeks (T0) the children were allocated into two groups, the FeNO was measured and the breath condensate was collected. Group A children were treated with the placebo (5 drops per day) and Group B children with L. reuteri (108CFU =5 drops per day) for 60 days. After the treatment period (T1), all patients were evaluated by medical examination, C-ACT, spirometry, FeNO measurement and exaled breath condensate analysis. The FeNO values showed a significant reduction (p=0,045) in L. reuteri group but not in the placebo group at the end of the treatment (T1). Furthermore, the cytokines exam showed an increase in IL-10 levels (p1 values and C-ACT score were found in both groups. In conclusion, these data showed that L. reuteri (108 CFU) was effective in reducing bronchial inflammation in asthmatic children. No significant effect was found on FEV1 values and C-ACT score, probably because we selected children with well controlled asthma.

Original languageEnglish
JournalJournal of Biological Regulators and Homeostatic Agents
Volume26
Issue number1 SUPPL
Publication statusPublished - 2012

Fingerprint

Inflammation
Asthma
Therapeutics
Spirometry
Placebos
Probiotics
Interleukin-10
Allergens
Oral Administration
Cytokines

Keywords

  • Asthma
  • FeNO
  • L.Reuteri DSM 17938
  • Probiotics

ASJC Scopus subject areas

  • Oncology
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)
  • Immunology and Allergy
  • Immunology
  • Endocrinology
  • Physiology
  • Cancer Research

Cite this

Miraglia Del Giudice, M., Maiello, N., Decimo, F., Fusco, N., D'Agostino B, B., Sullo, N., ... Perrone, L. (2012). Airways allergic inflammation and L. reuterii treatment in asthmatic children. Journal of Biological Regulators and Homeostatic Agents, 26(1 SUPPL).

Airways allergic inflammation and L. reuterii treatment in asthmatic children. / Miraglia Del Giudice, Michele; Maiello, N.; Decimo, F.; Fusco, N.; D'Agostino B, B; Sullo, N.; Capasso, M.; Salpietro, V.; Gitto, E.; Ciprandi, G.; Marseglia, G. L.; Perrone, L.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 26, No. 1 SUPPL, 2012.

Research output: Contribution to journalArticle

Miraglia Del Giudice, M, Maiello, N, Decimo, F, Fusco, N, D'Agostino B, B, Sullo, N, Capasso, M, Salpietro, V, Gitto, E, Ciprandi, G, Marseglia, GL & Perrone, L 2012, 'Airways allergic inflammation and L. reuterii treatment in asthmatic children', Journal of Biological Regulators and Homeostatic Agents, vol. 26, no. 1 SUPPL.
Miraglia Del Giudice M, Maiello N, Decimo F, Fusco N, D'Agostino B B, Sullo N et al. Airways allergic inflammation and L. reuterii treatment in asthmatic children. Journal of Biological Regulators and Homeostatic Agents. 2012;26(1 SUPPL).
Miraglia Del Giudice, Michele ; Maiello, N. ; Decimo, F. ; Fusco, N. ; D'Agostino B, B ; Sullo, N. ; Capasso, M. ; Salpietro, V. ; Gitto, E. ; Ciprandi, G. ; Marseglia, G. L. ; Perrone, L. / Airways allergic inflammation and L. reuterii treatment in asthmatic children. In: Journal of Biological Regulators and Homeostatic Agents. 2012 ; Vol. 26, No. 1 SUPPL.
@article{ccf7410e38644bf4b473be107c0dfc16,
title = "Airways allergic inflammation and L. reuterii treatment in asthmatic children",
abstract = "Recently, it has been hypothesized that the oral administration of specific live probiotic strains may have therapeutic potential in the treatment of allergic inflammation. The aim of this study was to evaluate the effect of the oral L. reuteri DSM 17938 administration (1X108CFU), in airways allergic inflammation in mild persistent asthmatic children. In this DBPC randomized study we selected 50 children (6-14 years old), affected by mild persistent asthma (GINA step 2) and allergic to HDM. At the run-in period (T-2), the children were submitted to medical examination, prick tests for the main respiratory allergens, spirometry and children asthma control test (C-ACT). We selected only the children with well controlled asthma (C-ACT >19 and FEV1>80{\%}). After two weeks (T0) the children were allocated into two groups, the FeNO was measured and the breath condensate was collected. Group A children were treated with the placebo (5 drops per day) and Group B children with L. reuteri (108CFU =5 drops per day) for 60 days. After the treatment period (T1), all patients were evaluated by medical examination, C-ACT, spirometry, FeNO measurement and exaled breath condensate analysis. The FeNO values showed a significant reduction (p=0,045) in L. reuteri group but not in the placebo group at the end of the treatment (T1). Furthermore, the cytokines exam showed an increase in IL-10 levels (p1 values and C-ACT score were found in both groups. In conclusion, these data showed that L. reuteri (108 CFU) was effective in reducing bronchial inflammation in asthmatic children. No significant effect was found on FEV1 values and C-ACT score, probably because we selected children with well controlled asthma.",
keywords = "Asthma, FeNO, L.Reuteri DSM 17938, Probiotics",
author = "{Miraglia Del Giudice}, Michele and N. Maiello and F. Decimo and N. Fusco and {D'Agostino B}, B and N. Sullo and M. Capasso and V. Salpietro and E. Gitto and G. Ciprandi and Marseglia, {G. L.} and L. Perrone",
year = "2012",
language = "English",
volume = "26",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "1 SUPPL",

}

TY - JOUR

T1 - Airways allergic inflammation and L. reuterii treatment in asthmatic children

AU - Miraglia Del Giudice, Michele

AU - Maiello, N.

AU - Decimo, F.

AU - Fusco, N.

AU - D'Agostino B, B

AU - Sullo, N.

AU - Capasso, M.

AU - Salpietro, V.

AU - Gitto, E.

AU - Ciprandi, G.

AU - Marseglia, G. L.

AU - Perrone, L.

PY - 2012

Y1 - 2012

N2 - Recently, it has been hypothesized that the oral administration of specific live probiotic strains may have therapeutic potential in the treatment of allergic inflammation. The aim of this study was to evaluate the effect of the oral L. reuteri DSM 17938 administration (1X108CFU), in airways allergic inflammation in mild persistent asthmatic children. In this DBPC randomized study we selected 50 children (6-14 years old), affected by mild persistent asthma (GINA step 2) and allergic to HDM. At the run-in period (T-2), the children were submitted to medical examination, prick tests for the main respiratory allergens, spirometry and children asthma control test (C-ACT). We selected only the children with well controlled asthma (C-ACT >19 and FEV1>80%). After two weeks (T0) the children were allocated into two groups, the FeNO was measured and the breath condensate was collected. Group A children were treated with the placebo (5 drops per day) and Group B children with L. reuteri (108CFU =5 drops per day) for 60 days. After the treatment period (T1), all patients were evaluated by medical examination, C-ACT, spirometry, FeNO measurement and exaled breath condensate analysis. The FeNO values showed a significant reduction (p=0,045) in L. reuteri group but not in the placebo group at the end of the treatment (T1). Furthermore, the cytokines exam showed an increase in IL-10 levels (p1 values and C-ACT score were found in both groups. In conclusion, these data showed that L. reuteri (108 CFU) was effective in reducing bronchial inflammation in asthmatic children. No significant effect was found on FEV1 values and C-ACT score, probably because we selected children with well controlled asthma.

AB - Recently, it has been hypothesized that the oral administration of specific live probiotic strains may have therapeutic potential in the treatment of allergic inflammation. The aim of this study was to evaluate the effect of the oral L. reuteri DSM 17938 administration (1X108CFU), in airways allergic inflammation in mild persistent asthmatic children. In this DBPC randomized study we selected 50 children (6-14 years old), affected by mild persistent asthma (GINA step 2) and allergic to HDM. At the run-in period (T-2), the children were submitted to medical examination, prick tests for the main respiratory allergens, spirometry and children asthma control test (C-ACT). We selected only the children with well controlled asthma (C-ACT >19 and FEV1>80%). After two weeks (T0) the children were allocated into two groups, the FeNO was measured and the breath condensate was collected. Group A children were treated with the placebo (5 drops per day) and Group B children with L. reuteri (108CFU =5 drops per day) for 60 days. After the treatment period (T1), all patients were evaluated by medical examination, C-ACT, spirometry, FeNO measurement and exaled breath condensate analysis. The FeNO values showed a significant reduction (p=0,045) in L. reuteri group but not in the placebo group at the end of the treatment (T1). Furthermore, the cytokines exam showed an increase in IL-10 levels (p1 values and C-ACT score were found in both groups. In conclusion, these data showed that L. reuteri (108 CFU) was effective in reducing bronchial inflammation in asthmatic children. No significant effect was found on FEV1 values and C-ACT score, probably because we selected children with well controlled asthma.

KW - Asthma

KW - FeNO

KW - L.Reuteri DSM 17938

KW - Probiotics

UR - http://www.scopus.com/inward/record.url?scp=84873077499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873077499&partnerID=8YFLogxK

M3 - Article

C2 - 22691248

AN - SCOPUS:84873077499

VL - 26

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 1 SUPPL

ER -